Pacira Pharmaceuticals ( (PCRX) ) just unveiled an update.
On April 7, 2025, Pacira BioSciences announced a settlement with Fresenius Kabi and others regarding patent litigations for EXPAREL®, allowing Fresenius to sell limited volumes of a generic version in the U.S. starting in 2030, with unlimited sales permitted from 2039. This agreement resolves ongoing litigations, provides clarity on EXPAREL’s exclusivity, and involves a $7 million payment to Fresenius, potentially impacting Pacira’s market strategy and stakeholder interests.
Spark’s Take on PCRX Stock
According to Spark, TipRanks’ AI Analyst, PCRX is a Neutral.
Pacira Pharmaceuticals has a balanced stock score, driven by strong cash flow and promising future guidance from recent earnings calls. However, profitability challenges and a negative P/E ratio weigh on its valuation. The technical indicators are neutral, and recent corporate events suggest a strategic focus on growth, which could improve future performance if successfully executed.
To see Spark’s full report on PCRX stock, click here.
More about Pacira Pharmaceuticals
Pacira BioSciences, Inc. is a leader in innovative, non-opioid pain therapies, offering products like EXPAREL®, ZILRETTA®, and iovera°. The company focuses on transforming patient lives through non-opioid pain management solutions and is advancing the development of PCRX-201 for treating prevalent diseases like osteoarthritis.
YTD Price Performance: 26.02%
Average Trading Volume: 867,869
Technical Sentiment Signal: Buy
Current Market Cap: $1.07B
Find detailed analytics on PCRX stock on TipRanks’ Stock Analysis page.